Member Info for BuenaVista

Check out the posting history guys.

Claims to have bought low and sold high, then back in again around the 50s. I've no reason to disbelief this.

Just don't understand the comment about "AVACTA competitors are making much quicker gains in their treatment research". Surely if you've been following your investment, you'll know precisely what's been happening with AVA6000 and why we're where we are? Or do you just not understand the pharmaceutical R&D process?

Looks like waggy's office is open over the Christmas-New Year period. Not exactly the A Team!

AS seems to have a nose for disruptive or game-changing tech. This is the direction I'd like to see Avacta move - incubator and early-stage developer of new tech for pharma that can be taken to market by others, either the acquired original inventor company or licensed out.

AS is Chair of SPARTA Biodiscovery.
https://www.imperial.ac.uk/news/239811/new-startup-help-pharmaceutical-companies-develop/amp/

What have you been buying recently Seg? :)

Still waiting for the OP to justify the "spurious claims" spurious claim...

Quite. Media will be much more amenable to another Avacta story post trial results media blitz.

"[Aptamer] is struggling to recruit more scientists, in part because of a lack of affordable housing in York, and the difficulty of hiring Europeans following Brexit."

Europeans more agreeable in London!

Q.E.D.

JamesSimon (SimonJames before he was banned) gives no evidence to justify his assertion.

A reminder to new investors:

- Bashers never bash a bad stock
- Bashers bash the stock of small companies with potential
- Bashers post many times a day
- Bashers repeatedly bring up old news
- Bashers will distort the truth
- Bashers play on your lack of knowledge
- Bashers play on your lack of patience
- Bashers make statements they know you won't check
- Bashers play on your laziness
- The basher's purpose is to bring the share price down

The best way to protect yourself is to be prepared and don't engage with the basher!

Read https://bashershandbook.blogspot.com/

Please give examples of corruption or ineptness by AB Ttnyr001 you worthless piece of excrement.

A reminder to naive investors:

- Bashers never bash a bad stock
- Bashers bash the stock of small companies with potential
- Bashers post many times a day
- Bashers repeatedly bring up old news
- Bashers will distort the truth
- Bashers play on your lack of knowledge
- Bashers play on your lack of patience
- Bashers make statements they know you won't check - OR EVEN CHALLEGE THEM ABOUT!
- Bashers play on your laziness
- The basher's purpose is to bring the share price down

The best way to protect yourself is to be informed and don't engage with the basher!

Read https://bashershandbook.blogspot.com/

Don't you mean a perfect orgasm Groot?

Merry Christmas and a Happy and Prosperous New Year to one and all LTHs. Fingers crossed for relief, and just possibly cures, for cancer sufferers in the near future.

...A person searching for meaning in a world she doesn't understand. More sense in Kim K's right butt cheek.

Do you think they would announce that the press were being invite? I don't think they would.

NR11 raises the very good suggestion of the press attending the Science Day. Would it be too technical for the science correspondents of the dailies, weeklies and broadcasters? Their decision I guess. However it would be great to have Nature, Science, New Scientist, Scientific American, etc and representatives of the various oncology journals and societies there to hear the detail first-hand!

There may well be other news released between the trial update RNS and the Science Day if Avacta are to give updates on their five programmes at the Science Day event and any AVA3996 and TMAC news must come after the trial update news. Such news may be in the same RNS but that would dilute the impact of Avacta's several shots on goal. Separate RNSes would help build the anticipation ahead of the Big Day.

The POINT Bio/Lantheus agreement was for PB's two lead candidates which are well into clinical development.
https://www.biospace.com/article/releases/point-biopharma-announces-closing-of-agreements-with-lantheus-holdings/

PB have a FAP targetting candidate in Phase 1 but their CanSEEK programme is still officially at the pre-clinical stage.

https://www.pointbiopharma.com/our-products/pipeline

PB are not involved with TMAC at all.

Well there are 5 programmes in the pipeline to be presented on the 23rd Feb so that's 5 Aces. OK, 4 Aces and a Joker.

Regulatory approval by the FDA, MHRA, EMA, etc will require proof that drug is efficacious for particular indications, specifying dose(s), route(s) and rate(s) of administration and dosing frequency. This is for Avacta's protection as much as anything since medical litigation is about the fastest way to ruin a small company.

Proof will be by comparison with standard of care for each indication (cancer type) and there will be lots of thought going into what is the best dose and rate of IV infusion (or possibly directly into tumours? - possible slow release formulation in the future?) and how often AVA6000 should be administered. If efficacy is good and side effects are minimal then, because doxorubicin is so well characterised, hopefully these Phase 2 trials will be 'a formality', particularly if AVA6000 is in Accelerated Approval.

Thanks for your responses (toatie also, but please learn how to respond within a thread!)

So if HC are owed money (are creditors) then their permission is needed?

But if HC can convert their loan to shares at, say 118p (a figure I seem to remember quoted somewhere), why wouldn't they jump at the opportunity of agreeing to a takeover at, say 500p, to bank a big profit (£1.33bn?) and move on to another loan opportunity somewhere else?